While chemotherapy and targeted therapy are successful in inducing the remission of
myeloid leukemia as acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) …

The cyclin‐D1 protein, which was found to be overexpressed in various human tumors,
promotes cell cycle progression from the G1 into the S phase. It is normally expressed at low …

In haematological cancers, malignant cells circulate in the blood and lymphatic system. This
may make leukaemic cells easier to target by immunotherapy than in other types of cancer …

Abstract Eukaryotic elongation factor-2 (eEF2) is overexpressed in many human cancers
and is an attractive target for cancer immunotherapy. The eEF2 derived polypeptides have …

With the recent progress in molecular biology and gene technology, many new cancer-
specific antigens have been identified. Many studies have demonstrated the role of HLA …

The present invention relates to peptides, nucleic acids and cells for use in
immunotherapeutic methods. In particular, the present invention relates to the …

A tumor-specific, bcr-abl-derived fusion peptide vaccine can be safely administered to
patients with chronic myelogenous leukemia (CML) and can elicit a bcr-abl peptide-specific …

Emerging preclinical and clinical data suggest that T cells recognize and kill malignant cells
in patients with hematological malignant disorders. The lower rates of relapse in the setting …

Vaccination with class I tumor peptides has been performed to induce tumor-reactive CD8+
T cells in vivo. However, the kinds of immune responses that vaccination might elicit in …

Peptides vaccination is an interesting approach to activate T-cells toward desired antigens
in hematological malignancies. In addition to classical tumor associated antigens, such as …